ATRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Atara Biotherapeutics Inc (ATRA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is experiencing significant price volatility, weak financial performance, and hedge fund selling pressure. While there are potential catalysts like FDA approval for tabelecleucel and a positive analyst rating, the lack of strong proprietary trading signals and the company's poor financials make it prudent to hold off on investing right now.
The MACD is positive but contracting, suggesting weakening momentum. RSI is neutral at 49.93, and moving averages are converging, indicating no clear trend. Key support is at 4.152, and resistance is at 5.658. The stock is currently trading near its pivot level of 4.905, showing limited upside potential in the short term.
Analyst price target raised to $25 with a Buy rating, citing potential FDA approval for tabelecleucel by January
Positive news sentiment with increased retail investor confidence and bullish sentiment on Stocktwits.
Updated long-term efficacy data for tabelecleucel and a potential resubmission to the FDA.
Hedge funds are selling, with a 192.53% increase in selling activity over the last quarter.
Significant revenue, net income, and EPS declines in Q3 2025, indicating poor financial health.
Stock trend analysis shows a likelihood of minor declines in the short term (-0.48% next day, -1.06% next week, -1.03% next month).
In Q3 2025, revenue dropped by 91.41% YoY to $3.45M, net income fell by 80.36% YoY to -$4.3M, and EPS declined by 89.08% YoY to -0.32. However, gross margin improved to 96.67%, up 19.23% YoY.
Canaccord raised the price target to $25 from $17 and maintained a Buy rating, citing a reasonable chance for FDA approval of tabelecleucel and a $40M milestone upon approval, which could reinvigorate the pipeline.
